Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $17M (down 58.8% year over year) with net income of −$13M.
Q3 2025 key financials · XBRL
- Revenue
- $17M
- −58.8% YoY · −39.4% QoQ
- Net income
- −$13M
- −94.8% YoY · −46.5% QoQ
- Operating margin
- -96.3%
- EPS (diluted)
- −$0.49
- −135.5% YoY · −44.1% QoQ
Source: XBRL data from the Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 10-Q on SEC EDGAR. USD.
Arcturus Therapeutics Holdings Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Federal shutdown risk added October 1, 2025 after failure to pass 2026 appropriations legislation
- Trade-secret litigation risk added September 23, 2025 following lawsuit against AbbVie, Capstan, and others
- CSL Seqirus collaboration risk increased after reports of CSL Limited potentially separating or spinning off its vaccine business
- Regulatory delays risk from shutdown affecting FDA, SEC, HHS, and U.S. Patent and Trademark Office activities
- Financing and liquidity risk from shutdown-related delays to capital-raising transactions and reduced securities trading volume
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcturus Therapeutics Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.